A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Superficial Bladder Cancer
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2017
At a glance
- Drugs SCH 721015 (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- Sponsors FKD Therapies
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
- 02 Feb 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 10 Aug 2015 Planned End Date changed from 1 May 2015 to 1 Dec 2015 ClinicalTrials.gov record.